Delivery Order SPE2DB22D2007-SPE2DB25FJ0QA

Award Date 4/10/25
Potential Completion Date 4/11/25
Potential Value $3.7K
Ultimate Awardee
Not listed
Federal Contract Vehicle
Set-Aside Type
No Set-Aside Used
Extent Competed
Full and Open Competition
Major Defense Program
Not listed
Pricing Type
Firm Fixed Price
Place of Performance
Conshohocken, PA 19428, USA
Solicitation Procedures
Negotiated Proposal / Quote
Number Of Offers Received
Not listed
Legislative Mandate
Not listed
National Interest Action
Not listed
Research Type
Not listed
Primary Consortia Member
Not listed
Similar Awards
This federal contract award was issued by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The $10,531.02 delivery order contract is for the provision of Ozempic 0.25-0.5 mg/dose pen 3 mL, a diabetes medication. The contract is a firm fixed-price, non-set-aside award with an ultimate completion date of April 16, 2025. AmerisourceBergen Drug Corp holds a substantial $999,999,999.00 Indefinite Delivery Contract...
This federal contract award, valued at $3,759.96, was issued by the Defense Logistics Agency (DLA) to Amerisourcebergen Drug Corp, a major pharmaceutical distributor. The contract is a delivery order for the supply of Ozempic 0.25-0.5 mg/dose pens, a diabetes treatment medication. The contract has a firm fixed price and an ultimate completion date of May 5, 2025. Amerisourcebergen Drug Corp is the prime contractor, and the contract is not designated as a set-aside. The company holds a...
This federal contract award, valued at $12,077.70, was issued by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor. The award is for the delivery of Ozempic 0.25-0.5 mg/dose pens, a diabetes medication, with a performance period through April 2025. The contract is a firm-fixed-price delivery order, with no set-aside designation, indicating open competition. AmerisourceBergen Drug Corp holds a substantial Indefinite Delivery Contract (IDC)...
This federal contract award was made by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The $8,664.24 firm fixed-price delivery order is for the supply of Ozempic 0.25-0.5 mg/dose pens, a diabetes medication. The contract has an ultimate completion date of May 7, 2025 and is not set aside. AmerisourceBergen Drug Corp holds a significant $999,999,999.00 Indefinite Delivery Contract (IDC) with the DLA Troop...
This federal contract award was issued by the Defense Logistics Agency (DLA) to Amerisourcebergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The award, valued at $55,679.41, is a firm fixed-price delivery order for OZEMPIC 0.25-0.5 MG/DOSE PEN 3ML, a diabetes medication. The contract has an ultimate completion date of May 21, 2024. Amerisourcebergen holds a $999,999,999 Indefinite Delivery Contract (IDC) with the DLA Troop Support Medical, which serves as...
This federal contract award was issued by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The $4,133.98 firm fixed price delivery order is for OZEMPIC 0.25-0.5 MG/DOSE PEN 3ML, a diabetes medication. The contract has an ultimate completion date of June 12, 2025. AmerisourceBergen Drug Corp holds a significant $999,999,999.00 Indefinite Delivery Contract (IDC) with the DLA Troop Support Medical, designated as...
This federal contract award, valued at $1,161.08, was issued by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The contract is a delivery order for the supply of Ozempic 0.25-0.5 mg/dose pens, a medication used to treat diabetes. The contract has a firm fixed price and an ultimate completion date of September 18, 2023. AmerisourceBergen holds a $999,999,999 Indefinite Delivery Contract (IDC) with the DLA...
This federal contract award, valued at $11,153.67, was issued by the Defense Logistics Agency (DLA) to Amerisourcebergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The contract is for the delivery of Ozempic 1 mg/dose (4 mg/3 ml) 3 ml, a diabetes medication. The contract has a firm fixed price and will run through May 7, 2025. Amerisourcebergen Drug Corp holds a significant Indefinite Delivery Contract (IDC) with the DLA Troop Support Medical, valued at...
This federal contract award, valued at $7,556.77, was issued by the Defense Logistics Agency (DLA) to Amerisourcebergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The contract is for the delivery of Ozempic 0.25-0.5 mg/dose pen 3mL, a diabetes treatment medication. This is a firm fixed-price delivery order contract with an ultimate completion date of April 11, 2025. The contract is not set aside and is open to full and open competition. Amerisourcebergen...
This federal contract award, valued at $22,559.76, was issued by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The award is a delivery order contract for the supply of Ozempic 0.25-0.5 mg/dose pens, a medication used to treat diabetes. The contract is a firm fixed-price, non-set-aside award with an ultimate completion date of April 29, 2025. AmerisourceBergen Drug Corp holds a significant Indefinite...
  • SPE2DB22D2007
    Indefinite Delivery Contract
  • SPE2DB22D2007-SPE2DB25FJ0QA
    Delivery Order

This federal contract award, valued at $3,702.78, was issued by the Defense Logistics Agency (DLA) to Amerisourcebergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The contract is for the delivery of Ozempic 0.25-0.5 mg/dose pens, a diabetes medication, with a performance period through April 2025.

Amerisourcebergen Drug Corp holds a significant Indefinite Delivery Contract (IDC) with the DLA Troop Support Medical, valued at $999,999,999.00, which serves as a comprehensive global pharmaceutical support vehicle through December 2026. This IDC enables the company to supply a wide range of pharmaceutical products and medical supplies to support military healthcare programs worldwide, including for the Defense Health Agency and U.S. Coast Guard. The contract award described is a delivery order under this larger IDC, and is not designated as a set-aside.

Generated 7/17/25, 6:27 PM